抗肿瘤坏死因子治疗后白癜风风险增加:10年人群队列研究
该研究利用韩国国民健康保险索赔数据库2007—2016年数据,纳入11,442例接受抗TNF治疗的强直性脊柱炎、克罗恩病或溃疡性结肠炎患者,并按年龄、性别和疾病1:1匹配未接受抗TNF治疗者。多变量Cox模型显示抗TNF组白癜风风险显著升高(HR=1.99,95%CI 1.06-3.75),斑秃风险两组无显著差异。
要点
- 抗TNF治疗者白癜风风险约为未暴露组的2倍,需警惕色素脱失。
- 年轻患者及使用依那西普者白癜风风险更高。
- 抗TNF治疗与斑秃风险无显著关联。
核心结论
- 抗TNF治疗与白癜风风险显著增加相关,与斑秃风险无显著关联。
- 结果提示细胞因子失衡可能参与白癜风发病机制。
研究设计与样本
- 基于韩国国民健康保险索赔数据库2007—2016年数据的10年人群队列研究。
- 纳入11,442例接受抗TNF治疗者,并按年龄、性别、疾病1:1匹配等量未暴露者。
- 采用多变量Cox比例风险模型比较两组白癜风与斑秃风险。
主要发现
- 抗TNF组白癜风风险显著高于未暴露组(HR=1.99,95%CI 1.06-3.75)。
- 白癜风发生率抗TNF组为5.9/10,000人年,未暴露组为2.5/10,000人年。
- 亚组分析中年轻患者及使用依那西普者白癜风风险更高。
- 斑秃风险两组间无显著差异。
关键数值与推荐
- 白癜风风险:HR=1.99,95%CI 1.06-3.75。
- 白癜风发生率:抗TNF组5.9/10,000人年,未暴露组2.5/10,000人年。
- 暴露组与未暴露组各11,442例。
临床怎么用
- 对接受抗TNF治疗的患者,尤其年轻及使用依那西普者,应关注白癜风样皮损。
- 出现色素脱失时需评估是否与抗TNF治疗相关并考虑皮肤科会诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-tumor necrosis factor-α (anti-TNF) therapy is used to treat a wide range of chronic inflammatory conditions. However, there has been an increasing number of reports of development of vitiligo and alopecia areata secondary to anti-TNF therapy. In this study, we investigated the risks of vitiligo and alopecia areata in patients with ankylosing spondylitis, Crohn's disease, or ulcerative colitis, who were treated with or without anti-TNF therapy using data from the Korean National Health Insurance Claims database from 2007 to 2016. The study comprised 11,442 patients treated with anti-TNF agents (anti-TNF group), and an equal number of age-, sex-, and disease- matched patients treated without anti-TNF agents (unexposed group). Multivariable Cox proportional hazards models were used to compare the risks of vitiligo and alopecia areata between the two groups. A significantly increased risk of vitiligo (hazard ratio = 1.99, 95% confidence interval = 1.06-3.75) was observed in the anti-TNF group compared to the unexposed group (5.9/10,000 person-years vs. 2.5/10,000 person-years). In subgroup analyses, younger patients and those treated with etanercept showed higher risks of vitiligo. The risk of alopecia areata was not significantly different between the two groups. Our results provide insight on the role of cytokine imbalance in the pathogenesis of vitiligo.
引用
- Bae JM, Kim M, Lee HH, et al. Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study. J Invest Dermatol. 2017. PMID: 29175284. doi:10.1016/j.jid.2017.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。